Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3C4E

Pim-1 Kinase Domain in Complex with 3-aminophenyl-7-azaindole

3C4E の概要
エントリーDOI10.2210/pdb3c4e/pdb
関連するPDBエントリー3C4C 3C4D 3C4F
分子名称Proto-oncogene serine/threonine-protein kinase Pim-1, IMIDAZOLE, N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine, ... (4 entities in total)
機能のキーワードpim-1, proto-oncogene, serine/threonine kinase, alternative initiation, atp-binding, cytoplasm, manganese, membrane, metal-binding, nucleotide-binding, nucleus, phosphoprotein, serine/threonine-protein kinase, transferase
由来する生物種Homo sapiens (human)
細胞内の位置Isoform 2: Cytoplasm. Isoform 1: Cell membrane: P11309
タンパク質・核酸の鎖数4
化学式量合計127184.51
構造登録者
Zhang, K.Y.J.,Wang, W. (登録日: 2008-01-29, 公開日: 2008-02-26, 最終更新日: 2024-02-21)
主引用文献Tsai, J.,Lee, J.T.,Wang, W.,Zhang, J.,Cho, H.,Mamo, S.,Bremer, R.,Gillette, S.,Kong, J.,Haass, N.K.,Sproesser, K.,Li, L.,Smalley, K.S.,Fong, D.,Zhu, Y.L.,Marimuthu, A.,Nguyen, H.,Lam, B.,Liu, J.,Cheung, I.,Rice, J.,Suzuki, Y.,Luu, C.,Settachatgul, C.,Shellooe, R.,Cantwell, J.,Kim, S.H.,Schlessinger, J.,Zhang, K.Y.,West, B.L.,Powell, B.,Habets, G.,Zhang, C.,Ibrahim, P.N.,Hirth, P.,Artis, D.R.,Herlyn, M.,Bollag, G.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Proc.Natl.Acad.Sci.Usa, 105:3041-3046, 2008
Cited by
PubMed Abstract: BRAF(V600E) is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer. Therefore, we pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular. By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered. PLX4720, a 7-azaindole derivative that inhibits B-Raf(V600E) with an IC(50) of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochemical and cellular assays. PLX4720 preferentially inhibits the active B-Raf(V600E) kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele. Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-Raf(V600E)-bearing tumor cell lines but not in cells lacking oncogenic B-Raf. In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-Raf(V600E)-positive cells. In B-Raf(V600E)-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity. The work described here represents the entire discovery process, from initial identification through structural and biological studies in animal models to a promising therapeutic for testing in cancer patients bearing B-Raf(V600E)-driven tumors.
PubMed: 18287029
DOI: 10.1073/pnas.0711741105
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.98 Å)
構造検証レポート
Validation report summary of 3c4e
検証レポート(詳細版)ダウンロードをダウンロード

247035

件を2026-01-07に公開中

PDB statisticsPDBj update infoContact PDBjnumon